Dr. Shaughnessy on the Promise of CAR T-Cell Therapy in Hematologic Malignancies

Video

Paul J. Shaughnessy, MD, discusses the promising future of CAR T-cell therapy in relapsed/refractory hematologic malignancies.

Paul J. Shaughnessy, MD, hematologist, oncologist, and medical director of Adult Blood and Marrow Transplant Program, at the Methodist Hospital, discusses the promising future of CAR T-cell therapy in relapsed/refractory hematologic malignancies.

Patients with relapsed/refractory disease have always been a difficult-to-treat patient population, says Shaughnessy, who adds that it may be beneficial to move effective therapies into earlier-line settings.

To date, ongoing randomized studies are comparing the safety and efficacy of CAR T-cell therapy with other standards of care in both non-Hodgkin’s lymphoma and multiple myeloma.

Many are hopeful that, over time, these trials will transform the armamentarium in hematologic oncology, allowing patients to be treated more effectively with fewer adverse effects, Shaughnessy concludes.

Recent Videos
Haydar Frangoul, MD, the medical director of pediatric hematology/oncology at Sarah Cannon Research Institute and Pediatric Transplant and Cellular Therapy Program at TriStar Centennial
David Barrett, JD, the chief executive officer of ASGCT
Georg Schett, MD, vice president research and chair of internal medicine at the University of Erlangen – Nuremberg
David Barrett, JD, the chief executive officer of ASGCT
Bhagirathbhai R. Dholaria, MD, an associate professor of medicine in malignant hematology & stem cell transplantation at Vanderbilt University Medical Center
Caroline Diorio, MD, FRCPC, FAAP, an attending physician at the Cancer Center at Children's Hospital of Philadelphia
R. Nolan Townsend; Sandi See Tai, MD; Kim G. Johnson, MD
Daniela van Eickels, MD, PhD, MPH, the vice president and head of medical affairs for Bristol Myers Squibb’s Cell Therapy Organization
Paul Melmeyer, MPP, the executive vice president of public policy & advocacy at MDA
© 2024 MJH Life Sciences

All rights reserved.